Unknown

Dataset Information

0

Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.


ABSTRACT: Passive immunotherapy, i.e., the administration of exogenous antibodies that recognize a specific target antigen, has gained significant momentum as a potential treatment strategy for several central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and brain cancer, among others. Advances in antibody engineering to create therapeutic antibody fragments or antibody conjugates have introduced new strategies that may also be applied to treat CNS disorders. However, drug delivery to the CNS for antibodies and other macromolecules has thus far proven challenging, due in large part to the blood-brain barrier and blood-cerebrospinal fluid barriers that greatly restrict transport of peripherally administered molecules from the systemic circulation into the CNS. Here, we summarize the various passive immunotherapy approaches under study for the treatment of CNS disorders, with a primary focus on disease-specific and target site-specific challenges to drug delivery and new, cutting edge methods.

SUBMITTER: Kumar NN 

PROVIDER: S-EPMC7234797 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Kumar Niyanta N NN   Pizzo Michelle E ME   Nehra Geetika G   Wilken-Resman Brynna B   Boroumand Sam S   Thorne Robert G RG  

Bioconjugate chemistry 20181024 12


Passive immunotherapy, i.e., the administration of exogenous antibodies that recognize a specific target antigen, has gained significant momentum as a potential treatment strategy for several central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and brain cancer, among others. Advances in antibody engineering to create therapeutic antibody fragments or antibody conjugates have introduced new strategies that may also be applied to treat  ...[more]

Similar Datasets

| S-EPMC5398760 | biostudies-literature
| S-EPMC4052367 | biostudies-literature
| S-EPMC7771318 | biostudies-literature
| S-EPMC10598668 | biostudies-literature
| S-EPMC8311521 | biostudies-literature
| S-EPMC8278144 | biostudies-literature
| S-EPMC10076750 | biostudies-literature
| S-EPMC2603083 | biostudies-literature
| S-EPMC8988043 | biostudies-literature
| S-EPMC7857417 | biostudies-literature